

Figure S1 Characterization of BMMSCs from *TERT^{-/-}***mice.** (A) Western blot showed no TERT expression in *TERT^{-/-}***BMMSCs.** Quantitative PCR showed that *TERT* expression was maintained at relatively a high level from P0 to P2 in WT BMMSCs, these cells were used in this study. However, the expression levels of *TERT* were significantly decreased in passage 5 and became undetectable in passage 10. On the other hand, *TERT* expression was undetectable in *TERT^{-/-}* BMMSCs from p0 to p10. (B) TRAP-ELISA telomere length analysis showed that *TERT^{-/-}* BMMSCs had no telomerase activity when compared to WT BMMSCs. (C) *TERT* siRNA significantly knocked down TERT expression, assessed by Western blot. (D) Telomerase activity was significantly decreased in *TERT* siRNA-treated BMMSCs by TRAP-ELISA telomere length analysis. (E-F) *TERT^{-/-}* BMMSCs showed downregulation of the osteogenic genes *runx2* and *ocn* (E) and bone nodule formation by alizarin red staining (F). (G-H) *In vitro* adipogenesis evaluation showed that *TERT^{-/-}* BMMSCs had elevated expression of *pparg2* and *lpl* genes (G), and Oil red-O staining showed that *TERT^{-/-}* BMMSCs had increased capacity to differentiate into adipocytes (H). Vehicle: scrambled siRNA-treated BMMSCs. Error bars present the s.d. from three independent experiments (***p<0.005, *p<0.05).